All Work

Chris Lange

Why Cara Therapeutics Shares Are Soaring

Cara Therapeutics shares made a solid gain on Wednesday after the firm announced that it has licensed rights to commercialize Korsuva injection for the treatment of chronic kidney disease-associated pruritus in dialysis patients.

Chris Lange · 8 years ago

How Tiffany Blew Out Its Q1

Tiffany released better-than-expected fiscal first-quarter financial results before the markets opened on Wednesday.

Chris Lange · 8 years ago

What to Look For in Target’s Q1 Report

Target is scheduled to release its fiscal first-quarter financial results before the markets open on Wednesday. What should investors look for in the report?

Chris Lange · 8 years ago

Amgen Wins Another FDA Approval

Amgen shares made a slight gain on Tuesday after it was announced that the FDA approved its treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture.

Chris Lange · 8 years ago

Monday’s Biggest Winners and Losers in the S&P 500

Monday was a positive day for the broad U.S. markets. All three of the major averages started out positive for the day and held on to their gains throughout the session, with the Dow…

Chris Lange · 8 years ago

EVO Payments Closes in on IPO

Global merchant acquirer and payment processor EVO Payments expects to price its 14 million shares to result in an initial public offering valued up to more than $257 million.

Chris Lange · 8 years ago

Dova Pharmaceuticals Slumps Despite FDA Approval

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) shares dropped on Monday following a critical update from the U.S. Food and Drug Administration (FDA) on one of its subsidiaries. Essentially the agency granted a Priority Review for…

Chris Lange · 8 years ago

Is the Worst Over for Snap?

Snap has been no stranger to analysts slashing their price targets, but when one of the bears thinks the worst may be over that is worth investors’ consideration.

Chris Lange · 8 years ago